Chantix is the US trading name for the drug varenicline, developed by Pfizer and released for general use in 2006. It has received some exceptional media attention due to its (claimed) success rates. Pfizer’s own website claims a 44% success rate which makes for a very interesting and potentially profitable drug. The more commonly accepted ’success rate’ is only 22% however.
As with Zyban, the other well-known aid for smoking cessation, there are a number of side effects to be taken into consideration with Chantix.
